ESMO 2021 | MGC018 in patients with advanced solid tumors

Eugene Shenderov, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, gives an update on the Phase I cohort expansion of the clinical trial (NCT03729596) investigating the use of MGC018, an anti-B7-H3 antibody-drug conjugate containing duocarmycin, to treat patients with advanced solid tumors. The preliminary data focuses on patients with non-small cell lung cancer and metastatic castration-resistant prostate cancer. MGC018 shows strong efficacy, with over half of evaluable patients showing a decrease of more than 50% of prostate-specific antigen (PSA) and several patients showing promising radiographic responses. Treatment-associated adverse events were common (88% of patients) and the tolerability of the drug needs to be improved. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.